India's New Neurological Frontier: The Dawn of Adaptive Parkinson's Tech

BENGALURU, India – July 21, 2026

For the millions in India grappling with Parkinson's disease, life is often a negotiation with a body that feels increasingly alien. The tremors, stiffness, and loss of voluntary movement are relentless. For years, Deep Brain Stimulation (DBS) has offered a lifeline—a surgically implanted device acting as a 'pacemaker for the brain,' delivering constant electrical impulses to regulate faulty neural circuits. But what if that pacemaker could do more than just follow a preset rhythm? What if it could listen, think, and adapt in real time?

This is the promise of Adaptive Deep Brain Stimulation (aDBS), a technology that is not just an incremental update but a paradigm shift in neuromodulation. And this week, India's medical community formally signaled its intent to embrace this future. Manipal Hospital Sarjapur Road became the focal point for this shift, hosting the country's first-ever scientific summit dedicated exclusively to aDBS. The event drew over 80 of the nation's top neurologists and neurosurgeons to Bengaluru, not just to hear about a new device, but to collectively map out the next chapter in treating movement disorders.

The Intelligent Implant: A New Paradigm for Parkinson's Care

At its core, aDBS transforms a monologue into a dialogue. Conventional DBS delivers continuous, pre-programmed stimulation, which, while effective, can be a blunt instrument. It doesn't account for the fluctuating needs of a patient throughout the day—whether they are resting, walking, or experiencing stress. Adaptive DBS, by contrast, incorporates sophisticated sensing technology that constantly monitors the brain's own electrical signals. It 'listens' for the specific biomarkers of symptoms and intelligently adjusts its stimulation, delivering therapy only when and how it's needed.

"Adaptive Deep Brain Stimulation represents the next milestone in the evolution of neuromodulation," said Dr. Shiva Kumar R, Head and Senior Consultant in Neurology at Manipal Hospital Sarjapur Road, during the summit. He explained that his institution has become one of the country's leading centers for the therapy. "Our experience has demonstrated its clinical efficacy in delivering more personalised treatment for patients with Parkinson's disease and movement disorders."

The implications are profound. This personalized approach promises more consistent symptom control while potentially reducing the side effects associated with over-stimulation, such as speech or balance issues. Furthermore, by optimizing energy use, early data suggests the implanted device's battery life could be significantly extended, reducing the frequency of replacement surgeries. The technology, which received its commercial launch in India from Medtronic in April 2026, is being hailed as a transformative step toward truly individualized medicine.

Bengaluru at the Epicenter: Charting the Course for aDBS Adoption

The Manipal DBS Summit 2026 was more than an academic conference; it was a declaration of intent. While the first clinical activations of aDBS in India occurred in March at centers like Apollo Hospitals Chennai and KIMS Hospitals, this summit marked the first concerted effort to build a national consensus and share early-stage knowledge. The one-day meeting was a whirlwind of expert lectures, panel debates, and hands-on programming sessions designed to rapidly scale up expertise.

"Academic collaboration plays a vital role in advancing patient care," commented Deepak Venugopal, Regional Chief Operating Officer for Manipal Hospitals, in his inaugural address. He emphasized the hospital's commitment to "creating platforms that bring together the best clinicians from across the country to share knowledge, discuss emerging technologies and collectively shape the future of healthcare."

This collaborative spirit is embedded in the Manipal network's strategy. Dr. Raghavendra S, Director of Epilepsy Services, highlighted how the group has cultivated specialized 'centres of excellence' across Bengaluru. "While Manipal Hospital Sarjapur Road has established itself as a leader in Deep Brain Stimulation and movement disorders, Manipal Hospital Yeshwanthpur has built strong expertise in epilepsy surgery, and Manipal Hospital Millers Road continues to excel in comprehensive stroke care," he explained. This ecosystem approach provides a powerful foundation for pioneering complex therapies like aDBS.

The Double-Edged Sword of Innovation: Access and Affordability

Beneath the surface of this technological enthusiasm lies a more complex reality. The arrival of aDBS in India is a story of two intertwined trends: the nation's rapid ascent as a hub for advanced medical care and the persistent challenge of equitable access. India bears a heavy Parkinson's burden, accounting for an estimated 10% of the global caseload—a number projected to swell as the population ages.

While India has become a global destination for affordable conventional DBS surgery, the cost of next-generation adaptive systems presents a new hurdle. For now, the technology remains the preserve of top-tier private hospitals in major metropolitan areas. This creates a potential chasm between those who can access this state-of-the-art care and the vast majority who cannot. As with many cutting-edge technologies, the initial wave of adoption is concentrated in the hands of a few, raising critical questions for policymakers and healthcare providers about how to broaden access in a country of 1.4 billion people.

The summit itself, by focusing on training and knowledge dissemination, is a crucial first step in addressing this. By empowering more specialists, the groundwork is being laid for the technology to, hopefully, diffuse beyond the initial handful of elite institutions. But the path from a breakthrough in Bengaluru to routine availability in a Tier-2 city is a long one, paved with challenges of cost, infrastructure, and training.

Beyond the Summit: The Future of Neuromodulation in India

As the summit concluded, the consensus was clear: aDBS is not a destination but a doorway to a new era. The technology's ability to record long-term brain activity opens up unprecedented research opportunities, allowing scientists to understand neurological diseases with a clarity never before possible.

Dr. Ajay Hegde, a Consultant Functional Neurosurgeon at Manipal Hospital Sarjapur Road, captured this forward-looking sentiment. "Advancements in neuromodulation are redefining the way we approach complex neurological disorders," he noted. "Platforms like the Manipal DBS Summit provide an invaluable opportunity for neurosurgeons and neurologists to exchange clinical experiences... and collectively enhance patient care. Continuous academic collaboration is essential."

The Manipal summit has fired the starting gun, initiating a national conversation on how to best integrate this intelligent technology into clinical practice. The challenge now is to ensure the momentum is sustained, translating the excitement from the conference hall into tangible benefits for patients across the country, and navigating the complex interplay of innovation, cost, and access that will define the future of neurological care in India.